Skip to Main Content

Paper Details

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Eur Urol
32
2023
Advanced Prostate Cancer, Patients, advanced prostate cancer, cancer, locally advanced prostate cancer, metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer, oligometastatic and oligoprogressive prostate cancer, patient, patients, prostate cancer
Author NameAffiliation
Johann S de BonoThe Institute of Cancer Research, UK Royal Marsden Hospital
Nicolas MottetUniversity Jean Monnet
Eric J SmallUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
Emmanuel S AntonarakisMasonic Cancer Center, University of Minnesota
Gerhardt AttardUniversity College London Cancer Institute
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Anders BjartellSkane University Hospital
Alberto BrigantiIRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University
Robert G BristowUniversity of Manchester, UK Christie NHS Trust and CRUK Manchester Institute and Cancer Centre
Heather H ChengFred Hutchinson Cancer Center, University of Washington
Kim N ChiUniversity of British Columbia
Rosalind A EelesThe Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Eleni EfstathiouHouston Methodist Cancer Center
Christopher P EvansUniversity of California Davis School of Medicine
Felix Y FengUniversity of California San Francisco
Mark FrydenbergMonash University
Martin E GleaveUniversity of British Columbia
Celestia S HiganoUniversity of British Columbia
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University
Brandon A MahalUniversity of Miami Sylvester Cancer Center
Joaquin MateoVall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital
Niven MehraRadboud University Medical Center
Michael J MorrisMemorial Sloan Kettering Cancer Center
Declan G MurphyPeter MacCallum Cancer Centre, University of Melbourne
Paul L NguyenBrigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
William K OhIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute
Piet OstGhent University
Colin C PritchardUniversity of Washington
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Robert E ReiterUniversity of California Los Angeles
Mark A RubinBern Center for Precision Medicine and Department for Biomedical Research
Mark A RubinBern Center for Precision Medicine and Department for Biomedical Research
Fred SaadCentre Hospitalier de Universite de Montreal
Oliver SartorTulane Cancer Center
Howard I ScherMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Daniel E SprattUniversity Hospitals Seidman Cancer Center
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Center, New York Presbyterian Hospital
Mary-Ellen TaplinDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Koc University Hospital
Inge M van OortRadboud University Medical Center
Neha VapiwalaAbramson Cancer Center, University of Pennsylvania
Evan Y YuUniversity of Washington and Fred Hutchinson Cancer Center
Almudena ZapateroHospital Universitario de La Princesa, Health Research Institute
  • 1 - 45

Datasets